Argenx reports half year 2023 financial results and provides second quarter business update

$269 million in second quarter vyvgart® (efgartigimod alfa-fcab) global net product sales vyvgart® hytrulo now available in the u.s. with first vials shipped in july global vyvgart expansion continued with commercial launch in italy and distribution agreement with handok in south korea topline results from advance-sc and address expected in fourth quarter of 2023 management to host conference call today at 2:30 pm cet (8:30 am et) july 27 , 202 3 amsterdam , the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2023 financial results and provided a second quarter business update. “we are thrilled to see the momentum continue across all aspects of our business, with a catalyst-rich first half of the year.
ARGX Ratings Summary
ARGX Quant Ranking